



Lene Jensen,
Director
Sjældne Diagnoser
Blekinge Boulevard 2
DK - 2630 Taastrup
Denmark

11 January 2024

Dear Lene,

2023-0079 Confirmation of Charitable Contribution

Thank you for your request for funding for Sjældne Diagnoser. Amicus Therapeutics UK Limited (“Amicus”) is pleased to confirm funding of 35,000 DKK to support Sjældne Diagnoser’s Rare Disease Day campaign in 2024 which includes disease awareness and policy activities throughout the month of February. In 2024, focus will be on the importance of the small voluntary rare associations for community. Activities include:

- Campaign activities in social media during February 2024
- Events on Rare Disease Day, February 29 2024
- Rare Prize 2024

For clarity, Sjældne Diagnoser will be solely responsible for organising and implementing the activities outlined in the request letter. Amicus will have no influence over the content and will have no commercial interest or gain from the funding provided for this activity and any materials generated and distributed as a result of this charitable contribution. Final editorial control and responsibility for the Rare Disease Day campaign organised by Sjældne Diagnoser always strictly remains with Sjældne Diagnoser.

Sjældne Diagnoser agrees that all activities conducted by the organisation that are funded by Amicus will be conducted in line with local regulations and codes. The funding is not for any activities or materials that mention any branded products or product names. In addition, since Amicus is based in UK it must comply with Association of the British Pharmaceutical Industry (ABPI) Code of Practice (full details can be found here [https://https://www.abpi.org.uk/reputation/abpi-2021-code-of-practice](https://www.abpi.org.uk/reputation/abpi-2021-code-of-practice)).

As required by the ABPI Code and any local Codes, Amicus will ensure any funding provided is acknowledged and publicly declared, along with the nature of the company’s involvement. We request all patient organisations we work with report their funding sources as required and include funding received from Amicus.

To avoid any potential conflicts of interest, Sjældne Diagnoser must notify Amicus if any Officer or Beneficiaries of your organisation are working or involved in any organisation that is part of the government,

Job code: NP-NN-ABP-00020124. Date of preparation: January 2024.
Registered address: One Globeside, Fieldhouse Lane, Marlow, Buckinghamshire, SL7 1HZ
Company Registration No: 5541527
VAT No: 244 1100 62

providing a government service or in any organisation working or involved in a government agency. This includes any role making decisions on advising government of the regulation of medicines or prescribing policy or funding/provision of healthcare at a national or international level.

Amicus will not make use of Sjældne Diagnoser's logo or equivalent without your prior agreement. Likewise, any use of the Amicus logo by your organisation must be agreed beforehand and be in line with Amicus branding guidelines that will accompany the logo. Since the Rare Disease Day campaign will be delivered as a result of partial funding/support from Amicus, we request the following declaration is clearly stated and visible on materials from the outset: 'This campaign is supported by funding from Amicus Therapeutics UK Limited who have had no input into the organisation or the content of activity.'

Please sign and return a copy of this letter and send an invoice addressed to: Amicus Therapeutics UK, One Globeside, Fieldhouse Lane, Marlow, Bucks, SL7 1HZ, UK. Please ensure the invoice includes: **PO number 4089** which is unique to this request, the bank account information such as SWIFT code, account number, transit number. If you have any questions relating to this please contact patientadvocacyintl@amicusrx.com.

With kind regards,

DocuSigned by:
David Lewis 01 February 2024 | 04:38 EST
42BAF3BEBAB949A...
David Lewis
General Manager, UK, Ireland and Nordics

DocuSigned by: 03 February 2024 | 13:46 GMT
Adam Jones
A0F4DEE3AC5F4A3...
Adam Jones
Vice President, Medical Affairs

By signing below, Sjældne Diagnoser acknowledges receipt of this letter and accepts the terms of the financial contribution described above.

For and on behalf of Sjældne Diagnoser
Duly authorised by: Lene Jensen

Date: DocuSigned by:
Lene Jensen 12 februar 2024 | 10:12 EST
4AF0FE0921A54C4...

Certifikat for færdiggørelse

Kuvert-id: 01EA190500F4471D8854CCCC9E6E1E1

Status: Gennemført

Emne: Complete with DocuSign: 2023-0079 - Charitable Contribution letter rare diseases Denmark_Lene.docx

Kildekuvert:

Dokumentsider: 2

Underskrifter: 3

Kuvertskaber:

Certifikatsider: 5

Initialer: 0

Lisa Bashorum

Autonavigation: Aktiveret

3675 Market Street

Kuvertstempling: Aktiveret

Philadelphia, PA 19104

Tidszone: (UTC-05:00) Eastern Time (US & Canada)

lbashorum@amicusrx.com

IP-adresse: 86.128.247.117

Sporing af poster

Status: Original

Ihændeager: Lisa Bashorum

Sted: DocuSign

24-01-2024 17:45:36

lbashorum@amicusrx.com

Hændelser for underskriver**Underskrift****Tidsstempel**

David Lewis

dlewis@amicusrx.com

GM UK,I & Nordics

Sikkerhedsniveau: E-mail, Kontogodkendelse (valgfri)

DocuSigned by:

David Lewis
42BAF3BEBAB949A...

Sendt: 24-01-2024 17:49:19

Vist: 01-02-2024 04:38:44

Signeret: 01-02-2024 04:38:55

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse: 81.129.222.60

Oplysninger om elektroniske poster og underskrifter:

Tilbydes ikke via DocuSign

Adam Jones

ajones@amicusrx.com

Vice President, International Medical

Amicus Therapeutics

Sikkerhedsniveau: E-mail, Kontogodkendelse (valgfri)

DocuSigned by:

Adam Jones
A0F4DEE3AC5F4A3...

Sendt: 01-02-2024 04:38:57

Vist: 03-02-2024 08:46:35

Signeret: 03-02-2024 08:46:53

Vælg underskrift: Underskrevet på enhed

Brug af IP-adresse: 2.121.16.166

Oplysninger om elektroniske poster og underskrifter:

Tilbydes ikke via DocuSign

Lene Jensen

lj@sjældnediagnoser.dk

x

Sikkerhedsniveau: E-mail, Kontogodkendelse (valgfri)

DocuSigned by:

Lene Jensen
4AF0FE0921A54C4...

Sendt: 03-02-2024 08:46:55

Vist: 04-02-2024 10:38:46

Signeret: 12-02-2024 10:12:47

Vælg underskrift: Forudvalgt stil

Brug af IP-adresse: 152.115.40.130

Oplysninger om elektroniske poster og underskrifter:

Accepteret: 04-02-2024 10:38:46

Id: f042cd23-8f1d-474b-856c-92471087b4d0

Virksomhedens navn: Amicus Therapeutics

Hændelser for personlig underskriver**Underskrift****Tidsstempel****Hændelser for redaktørlevering****Status****Tidsstempel****Hændelser for agentlevering****Status****Tidsstempel****Hændelser for midlertidig levering****Status****Tidsstempel****Hændelser for certificeret levering****Status****Tidsstempel**

Hændelser for kopi (cc:)	Status	Tidsstempel
--------------------------	--------	-------------

Vidnehændelser	Underskrift	Tidsstempel
----------------	-------------	-------------

Notarhændelser	Underskrift	Tidsstempel
----------------	-------------	-------------

Hændelser for kuvertoversigt	Status	Tidsstempler
------------------------------	--------	--------------

Kuvert sendt	Med hash/krypteret	24-01-2024 17:49:19
Leveret certificeret	Sikkerhedskontrolleret	04-02-2024 10:38:46
Signering fuldført	Sikkerhedskontrolleret	12-02-2024 10:12:47
Gennemført	Sikkerhedskontrolleret	12-02-2024 10:12:47

Betalingshændelser	Status	Tidsstempler
--------------------	--------	--------------

Oplysninger om elektroniske poster og underskrifter

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Amicus Therapeutics (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Amicus Therapeutics:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: dataprivacyofficer@amicusrx.com

To contact us by paper mail, please send correspondence to:

Amicus Therapeutics

One Globe Side

Fieldhouse Lane

Marlow SL7 1HZ, NJ United Kingdom

To advise Amicus Therapeutics of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at dataprivacyofficer@amicusrx.com and in the body of such request you must state: your previous email address, your new email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Amicus Therapeutics

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to dataprivacyofficer@amicusrx.com and in the body of such request you must state your email address, full name, mailing address, and telephone number.

To withdraw your consent with Amicus Therapeutics

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to dataprivacyofficer@amicusrx.com and in the body of such request you must state your email, full name, mailing address, and telephone number. . .

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Amicus Therapeutics as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Amicus Therapeutics during the course of your relationship with Amicus Therapeutics.